David Sinclair· PhD
And rapamycin works by inhibiting mTOR. - Yeah, actually, TOR stands for Target Of Rapamycin. So that's how mTOR was discovered. And when you give animals rapamycin, you're mimicking low protein intake.
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
And rapamycin works by inhibiting mTOR. - Yeah, actually, TOR stands for Target Of Rapamycin. So that's how mTOR was discovered. And when you give animals rapamycin, you're mimicking low protein intake.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
rapamycin inhibits something called the mechanistic target of rapamycin they got very creative on the naming em tool tor would be a great superhero sounds like a he-man bad guy I'm Skeletor shoulda been an x-men it should have been so rapamycin inhibits that mTOR which is sort of the central nutrient sensor for amino acids
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.